At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
Influenza Vaccinebiological
Likely dose
Influenza Vaccine 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis
Shahid Beheshti University of Medical Sciences·observational·Posted Jan 26, 2009·Updated May 21, 2009
In Brief
An observational study evaluating Influenza Vaccine for Pulmonary Sarcoidosis. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Sarcoidosis
CountriesIran
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedJan 2009
Primary CompletionFeb 2009
Study CompletionMay 2009
TodayJul 2026
First PostedJan 26, 2009
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.4 years ago
Interventions
Influenza Vaccinebiological
One 0.5 ml dose of influenza vaccine injected intramuscular.